Introduction: New vaccines are being developed to improve the efficacy of seasonal influenza immunization in elderly persons aged C65 years. These products require clinical and economic evaluation to aid policy decisions. Electronic supplementary material The online version of this article (
Methods: To address this need, a two-part model has been developed, which we have applied to examine the potential clinical and economic impact of vaccinating elderly persons with adjuvanted trivalent inactivated influenza vaccine (aTIV) relative to conventional trivalent (TIV) and quadrivalent (QIV) vaccines. We compared outcomes in the US population for (1) aTIV in persons aged C65 years and QIV in all other age cohorts; (2) QIV in all cohorts; (3) TIV in all cohorts. Low, average, and high intensity seasons with low, average, and high vaccine match scenarios were compared.
Probabilistic sensitivity analysis was conducted within each discrete scenario to explore the impact of variation in model inputs on potential outcomes. with aTIV in the elderly versus QIV in the whole population ranged from $27 million (low intensity, low match) to $934 million (high intensity, high match). Univariate sensitivity analysis of relative vaccine prices in the average intensity, average match scenario indicated that aTIV could be marginally cost saving relative to QIV at the currently published Medicare price for influenza vaccines offering enhanced efficacy in the elderly. Elderly vaccination with aTIV was associated with a higher overall cost compared with TIV in only two scenarios (low intensity with average or high match); the incremental cost/QALY relative to TIV was $9980 in the average match scenario and
Results

INTRODUCTION
The clinical and economic burden of influenza is significant, particularly in vulnerable populations, such as children, persons with compromised immune function, and the elderly. Notably, the risk of influenza-related complications increases with age [1] [2] [3] , influenza-associated hospitalizations are most common among elderly aged C65 years (especially in those with underlying medical conditions) [4] [5] [6] [7] [8] , and up to 90% of influenza-attributable mortality is seen in this cohort [9] [10] [11] .
Significant direct healthcare costs are linked to influenza in persons aged C65 years [6] .
These costs are driven by substantial numbers of influenza-related hospitalizations, and are increasing as the overall population ages [9] . Moreover, influenza-related hospitalizations in the elderly are associated with significant disability and impairments in activities of daily living. These effects have societal implications as they can be long lasting, and catastrophic disability after influenza hospitalization is a significant problem in this age cohort [12, 13] . Influenza vaccination in the elderly provides substantial benefits [14] , and past cost-benefit and cost-effectiveness studies from a number of countries have indicated that this intervention in this age cohort is always cost-effective and is frequently cost saving [15] .
Influenza vaccination policy in most developed countries, therefore, targets people aged C65 years as part of the effort to reduce the mortality and disability burden in this population [16] .
The efficacy of conventional inactivated influenza vaccine [trivalent (TIV) or quadrivalent (QIV)] decreases with advancing age because of reduced production of vaccine-specific antibodies [17] . Attempts to increase immunogenicity have been made with alternatives such as high-dose TIV (60 lg of hemagglutinin (HA)/strain) [18] and an intradermal vaccine [19] . Constant evolution of the influenza strains in circulation further challenges vaccine protection with approximately 35% reduction in efficacy against mismatched versus matched strains [20, 21] . As a result, QIV may offer benefit in seasons where the B lineage selected for TIVs does not match the dominant circulating strain [22] . Notably, however, TIV adjuvanted with the squalene-containing oil-in-water emulsion MF59 (aTIV) increases seroprotection [23, 24] and has been associated with a 25% reduction in risk of hospitalization for influenza or pneumonia versus TIV in the elderly population aged C65 years [25] . Moreover, in the elderly, aTIV has been reported to provide better cross-reactivity against mismatched strains than conventional vaccine [26] .
As the economic burden of influenza is disproportionately concentrated in the elderly [27] , improvements in vaccine immunogenicity and efficacy in this group have economic implications that warrant investigation. Economic modeling is an important and generally accepted method for estimating the economic effects of an intervention [28] . A two-part epidemiologic and economic model was, therefore, developed to assess the clinical and economic impact of vaccination with aTIV in persons aged C65 years and QIV in those aged \65 years versus QIV or TIV in all age cohorts. As illustrated in Fig. 2 , in the proportion of the population that will be vaccinated (Cv i ), some people who receive vaccination are susceptible (S i ) and some are already protected by previous vaccination or influenza exposure (R i ). Among those not yet protected (S i ), vaccination can be successful (the individual enters compartment VR i ) or unsuccessful (enters compartment VS i ). Vaccine efficacy (1 -P i ) determines distributions over the VS i and VR i compartments. All persons already protected before vaccination (R i ) will move to compartment VR i .
METHODS
Scenarios of Interest
The rate at which individuals in age cohort i transition from susceptible S i to infected/ infectious I i is the force of infection, k i . Patients who are not fully protected after of the year and, therefore, cannot infect others (i.e., effectively removed from the simulation). Changes in the proportion of patients over the compartments are defined by the differential equations:
The force of infection k i (t) is the rate at which susceptible individuals in age cohort i are infected at time t. It is the summation of the rates of infection at time t from all infected/ infectious in age cohorts j:
where:
r is the transmissibility parameter. Inputs of the model include age-stratified population [34] , an age-stratified contact matrix (c) representing interactions between individuals in the population leading to spread of the disease ( [35] , adapted to fit this model's age structure; Table S1 ), duration of infection (1/t) (assumed gamma distribution with mean of 4 days and standard deviation of 1 day [36] [37] [38] , strain circulation [29] [30] [31] [32] [33] , vaccine coverage by age [39] , and vaccination efficacy by strategy by level of vaccine match to circulating strains by age [20, 21 25, 40] . The susceptibility u i , infectivity f j , and transmission r parameters are derived through a calibration process described below and in the ESM. Full details of these inputs are shown in Tables S1-S8.
Outcomes Module
The ''outcomes module'' calculates the outcomes associated with influenza according to a tree structure ( Fig. 3 ; Tables 1, 2 Given medical consultation, antivirals and/or other drugs might be prescribed (third and fourth chance nodes). The conditional probabilities of influenza-related complications can be influenced by the prescription of antivirals and other drugs. We assumed the risk of complications to be the same with and without vaccination (i.e., the risk of complications is entirely dependent on whether an individual is infected with influenza). The probability of hospitalization or death in the presence of a complication is the result of the calibration process described below. The conditional probabilities with their sources are shown in Table S9 .
Direct costs (US$) for medical care, including medical consultation, prescriptions for antivirals and other drugs [42] , and costs of complications with and without hospitalization [42, 43, 49] , were included (Table 1) . Indirect costs covered productivity losses based on the severity of complications [27] . QALY reductions for the duration of symptoms of influenza and its complications ( Table 2 ) and QALY losses due to life-years lost due to fatal complications were also included ( Table 3 ). Life-years and QALYs lost were discounted at 3% per annum.
Expected outcomes and costs for each new influenza case were calculated by multiplying the probability of each event as reflected in the final branches of the tree with the corresponding outcomes and costs. In combination with the incidence of influenza over the course of a 1-year period as estimated with the ''epidemiologic module'', the expected outcomes associated with influenza over this period were obtained.
Calibration of the Model
The model was calibrated to the age-stratified number of cases based on age-stratified estimated gross attack rates [27] and estimates of influenza incidence [27, 29, 50] by adjusting a factor for transmissibility (r) and age-specific factors for susceptibility (u i ). Conditional probabilities for hospitalization and death by complication according to age were then calibrated to literature-based estimates [27] (see the ESM for further detail).
Estimation of Model Outcomes
For each scenario and vaccination strategy of interest, we conducted a probabilistic analysis (second-order Monte Carlo simulation) by CVD with hospitalization All ages 6017 American Heart Association [43] which variation in the model input parameters (summarized with probability density functions) was propagated through the model to obtain distributions for the following outcomes of interest: number of influenza cases, complications, deaths, life-years lost, Assuming (a) 25% better efficacy of adjuvanted versus non-adjuvanted vaccine against any The breakeven analysis, which modeled a low intensity season in which the difference between elderly aTIV and QIV in number of cases was as close to zero as possible, showed that the prevalence of circulating mismatched strains would have to exceed 54.5% for QIV to offset the benefits of aTIV.
The potential impact of aTIV versus QIV vaccination in the elderly on costs was split evenly between direct savings ranging from $15 million (low intensity, low match) to $475 million (high intensity, high match) and indirect savings from $12 million to $459 million ( Fig. 5 ; Table 6 ). Elderly aTIV vaccination was associated with increased overall cost over TIV in only two scenarios (low intensity with average or high match) but still represented good value for money with an incremental cost/QALY relative to TIV of $9980 in the average match scenario and $28,800 in the high match scenario. In both these scenarios, however, elderly aTIV dominated QIV with lower cost (-$171,071; -$222,553) and higher QALYs (14,676; 17,136) . Univariate sensitivity analysis of relative vaccine prices in the average intensity, average match scenario indicated that aTIV could be marginally cost saving relative to QIV at current Medicare prices for influenza vaccines (Fig. 6 [51 -53] ).
Inspection of variability of results across scenarios showed that the outputs were most sensitive to vaccine match, followed by season intensity. The probabilistic nature of the model was illustrated by the probabilistic mean, low, and high estimates for each outcome within each discrete scenario, reflecting variation of inputs in observational studies and surveillance data.
DISCUSSION
We demonstrate that vaccination of persons aged C65 years with aTIV has the potential to provide clinical and economic benefit relative to QIV and TIV. The dynamic model described herein can be used to inform policy decisions regarding seasonal influenza vaccination. Similar dynamic compartmental models have Table 6 continued Probabilistic means (95% CrI)
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Average match High match QIV been described previously [54] [55] [56] [57] . Importantly, they enable herd immunity benefits of vaccination, which are not adequately addressed by static models, to be captured.
The use of dynamic models such as that described here to inform policy making in persons aged C65 years is particularly pertinent because significant healthcare costs are linked to influenza in this population [6] .
Note that the present analysis was based on the results of previous studies and other information from the literature, and did not involve the collection of any new data from human or animal subjects.
In the US, a very broad routine annual vaccination recommendation is in place (all persons aged C6 months with no contraindications) [58] . Moreover, the US Centers for Disease Control and Prevention (CDC) does not currently recommend any one influenza vaccine product over another in the elderly (i.e., no preference is expressed at present for QIV, high-dose, or adjuvanted vaccine over conventional TIV) [58] . As a result of recent studies indicating increased vaccine effectiveness of high-dose influenza vaccine in the over-65 population [59, 60] , there is sentiment towards using the high-dose vaccine in that population, despite the current lack of a preferential recommendation for its use. Additionally, as QIV supplies continue to increase within the US, there appears to be increasing support for its use in the general population, again despite the lack of a preferential recommendation for such use by the CDC. Both the QIV and high-dose TIV vaccines are covered by insurance in the US. Of note, the high-dose TIV is covered by the Medicare Part B program despite its higher cost; this is significant, as the majority of the over-65 population in the US is covered by this public payer [61] . Table 6 continued
Probabilistic means (95% CrI) The effectiveness of current vaccination recommendations in the elderly is under debate, as conventional vaccines are reported to provide suboptimal protection in this group [7] . High-dose TIV uptake in the elderly is expected to increase in the US and other countries in the near future, but there remains a need for additional vaccines offering enhanced immunogenicity in this population [62] . Adjuvantation of inactivated vaccines (e.g., with oil-in water adjuvants) has the potential to address unmet influenza vaccination needs in the elderly [16, 62] , and has been reported to provide better cross-reactivity against mismatched strains than conventional vaccines in the elderly in several studies [26, [63] [64] [65] . The potential for improved outcomes with adjuvanted vaccine was apparent from the model, which showed probabilistic mean reductions in clinical outputs and overall costs relative to QIV even in modeled low match seasons. The breakeven analysis carried out after the main simulations suggested that QIV would only offer incremental benefit over aTIV in the elderly if the proportion of mismatched strains in circulation was as high as 54.5% or above, a level which has not been observed in the US over the last 15 years.
Of note, high-dose TIV has been associated with a 24.2% increase in efficacy against laboratory-confirmed influenza [59] and a 22% increase in effectiveness for preventing probable influenza infections and hospitalizations in persons aged C65 years [60] . This suggests that economic comparisons of high-dose TIV with other inactivated influenza vaccine options using the model would be of considerable interest and could be the subject of a future analysis. For now, and on the basis of the data and assumptions built into the present model and the above observations with high-dose vaccine, we would expect such an analysis to yield results comparable to those obtained here with aTIV in subjects aged C65 years. Such a hypothesis would require future confirmation, however.
As reported above, the potential impact of aTIV versus QIV on costs was split evenly between direct and indirect savings. Direct cost savings were derived from reduced hospitalizations among the elderly, who experience increased serious influenza complication rates over younger populations [27] . Indirect cost savings accrued mainly from the impact on younger working relatives/ associates, who are likely to experience work interruptions due to the need for visitation and care giving, with accompanying losses of productivity [27] . Sensitivity analysis of vaccine prices in the average intensity, average match scenario indicated that aTIV could be marginally cost saving relative to QIV at current Medicare prices.
The importance of indirect protection of older persons through herd immunity effects is illustrated by experience of influenza outbreaks in residential institutions [5] . As mentioned earlier, the structure of the SIR model on which the analysis was based accounts for herd immunity effects, through which the elderly benefit from decreased transmission of influenza among the broader population as a result of vaccination [16] .
The data used to populate the model were subject to a number of limitations. Mannino et al.'s study [25] demonstrating the 25% c Fig. 4 Graphic summary of the main clinical and life-year outputs of the model. All values are probabilistic means (see Tables 4 and 5 for 95% credible intervals for probabilistically modeled values). aTIV adjuvanted TIV, QALY quality-adjusted life-year, QIV quadrivalent inactivated seasonal influenza vaccine, TIV trivalent inactivated seasonal influenza vaccine Fig. 4 continued reduction in risk of hospitalization for influenza or pneumonia versus TIV in adults aged C65 years was observational only, did not assess aTIV's impact on the reduction of influenza cases, and did not compare aTIV directly with QIV [25] . There was no stratification other than age in the model, with no account taken of chronic disease status or residential/contact status. The model does not account for adverse effects of influenza vaccination. In addition, costs were treated deterministically in the model even though significant variation occurs in clinical practice. Despite these limitations, the findings are in line with what would be expected for a vaccine offering enhanced immunogenicity that has a potentially positive effect on clinical outcomes and costs relative to conventional vaccines, given the known economic burden of influenza [66] and the public health and economic benefits of vaccination [66, 67] .
CONCLUSION
We have developed a dynamic model to assist vaccination policy decisions directing choices between different formulations of seasonal influenza vaccine. The US scenario modeled suggests that vaccination of persons aged C65 years with aTIV has the potential to provide clinical and economic benefit relative to QIV and TIV. We recommend further investigation of the clinical and economic impact of aTIV relative to other vaccine formulations in the elderly. Table 6 for 95% credible intervals for probabilistically modeled values). 
